BRIEF-Nabriva Therapeutics anticipate topline data from phase 3 trials in second half of 2017

* Nabriva therapeutics confirms no sample size adjustment

required for leap 1 phase 3 trial of lefamulin in community

acquired bacterial pneumonia

Read more

BRIEF-Trillium Therapeutics Inc intends to provide an update on ongoing TTI-621 trials

* Trillium Therapeutics Inc - intends to provide an update

on ongoing TTI-621 trials by year-end.

Read more

BRIEF-Becton Dickinson Q1 earnings per share $2.58

* Becton dickinson and co says raising expected full fiscal

year 2017 adjusted diluted earnings per share to $9.70 to $9.80

Read more

BRIEF-Exact Sciences says Cologuard included in medicare advantage advance notice, draft call letter

* Exact Sciences Corp says that Cologuard is included in

medicare advantage advance notice and draft call letter

Source text for Eikon:

Further company coverage:

Read more

BRIEF-Scandinavian ChemoTech signs second LOI in Philippines

Feb 2 (Reuters) - Scandinavian ChemoTech AB :

* Signs second Letter of Intent (LOI) in Philippines

Source text for Eikon:

Further company coverage:

(Gdynia Newsroom)

Read more

BRIEF-AstraZeneca CEO says MYSTIC cancer drug trial "not binary"

Feb 2 (Reuters) - Astrazeneca CEO Pascal Soriot told

reporters after Q4 results:

Read more

BRIEF-Dr. Lal Pathlabs declares interim dividend of 1.30 rupees per share

* Dr. Lal Pathlabs Ltd says have declared an interim

dividend of Rs. 1.30 per equity share

Source text - (Dr. Lal PathLabs Ltd has informed BSE that the

Board of Directors of the Company

at its meeting held on February 02, 2017, inter alia, have

declared an interim dividend of Rs. 1.30 per equity share (@ 13

% on a face value of Rs. 10/- per share) for the Financial Year

2016-17.)

Further company coverage:

Read more